Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, today announced a new investment in NephroDI Therapeutics, a US-based, near-clinical stage pharmaceutical company focusing on concentration disorders of the kidney. In conjunction with this investment, Bibhash Mukhopadhyay, Managing Partner at Sound Bioventures, will join NephroDI's Board of Directors.

NephroDI Therapeutics is a pharmaceutical company headquartered in Seattle, Washington, focused on developing and commercializing drugs to treat concentration disorders of the kidney. The company's lead program is NDI-5001, a novel kidney-targeted small molecule AMPK activator being developed as a potential first-in-class treatment of Congenital Nephrogenic Diabetes Insipidus.